GSKGlaxoSmithKlineSigning up patients
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Ovarian Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 690 (planned)
- Started
- Sep 8, 2026
- Main results expected
- May 21, 2030
- Fully finished
- Apr 22, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) by BICR
Measured over: Up to approximately 191 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07684612 · record last updated 2026-10-01 · checked 2026-11-09 15:47 UTC